The correlates of urinary albumin to creatinine ratio (ACR) in a high risk Australian aboriginal community

BMC Nephrology

Zhiqiang Wang¹  Wendy E Hoy¹  Zaimin Wang¹ 

[1] Center for Chronic Disease, School of Medicine, The University of Queensland, Royal Brisbane & Women’s Hospital, Herston, Brisbane, Queensland 4029, Australia

关键词: Aboriginal people;    ACR;    Overt albuminuria;    Microalbuminuria;    Albuminuria;   

Others  :  1082863
DOI  :  10.1186/1471-2369-14-176

 received in 2013-01-09, accepted in 2013-08-12,  发布年份 2013

【 摘 要 】

Background

Albuminuria marks renal disease and cardiovascular risk. It was estimated to contribute 75% of the risk of all-cause natural death in one Aboriginal group. The urine albumin/creatinine ratio (ACR) is commonly used as an index of albuminuria. This study aims to examine the associations between demographic factors, anthropometric index, blood pressure, lipid-protein measurements and other biomarkers and albuminuria in a cross-sectional study in a high-risk Australian Aboriginal population. The models will be evaluated for albuminuria at or above the microalbuminuria threshold, and at or above the “overt albuminuria” threshold with the potential to distinguish associations they have in common and those that differ.

Methods

This was a cross-sectional study of 598 adults aged 18–76 years. All participants were grouped into quartiles by age. Logistic regression models were used to explore the correlates of ACR categories.

Results

The significant correlates were systolic blood pressure (SBP), C-reactive protein (CRP), uric acid, diabetes, gamma-glutamyl transferase (GGT) (marginally significant, p = 0.054) and serum albumin (negative association) for ACR 17+ (mg/g) for men and 25+ for women. Independent correlates were SBP, uric acid, diabetes, total cholesterol, alanine amino transferase (ALT), Cystatin C and serum albumin (negative association) for overt albuminuria; and SBP, CRP and serum albumin only for microalbuminuria.

Conclusions

This is the most detailed modelling of pathologic albuminuria in this setting to date. The somewhat variable association with risk factors suggests that microalbuminuria and overt albuminuria might reflect different as well as shared phenomena.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Spencer J, Silva D, Hoy W: An epidemic of renal failure among Australian aboriginal. Med J Aust 1998, 168:537-541.
• [2]Cunningham J, Condon JR: Premature mortality in aboriginal adults in the Northern Territory. Med J Aust 1996, 165:309-312.
• [3]Veroni M, Gracey M, Rouse I: Patterns of mortality in Western Australian aboriginals, 1983–89. Int J Epidemiol 1994, 23:73-81.
• [4]Cass A, Cunningham J, Wang Z, Hoy W: Regional variation in the incidence of end-stage renal disease in Indigenous Australians. Med J Aust 2001, 175:24-27.
• [5]Wirta O, Pasternack A, Mustonen J, Laippala P: Renal and cardiovascular predictors of 9-year total and sudden cardiac mortality in non-insulin-independent diabetic subjects. Nephrol Dial Transplant 1997, 12:2612-2617.
• [6]Hoy WE, Wang Z, Baker PRA, Kelly AM: Reduction in natural death and renal failure from a systematic screening and treatment program in an Australian aboriginal community. Kidney Int 2003, 63(Suppl 83):S66-S73.
• [7]Hoy W, McDonald SP: Albuminuria: marker or target in Indigenous populations. Kidney Int 2004, 66(Suppl 92):S25-S31.
• [8]Hoy WE: Renal disease in aboriginal Australians. Med J Aust 1996, 165:126-127.
• [9]Wang Z, Hoy WE: The predictive value of albuminuria for renal and nonrenal natural deaths over 14 years follow-up in a remote aboriginal community. Clin Kidney J 2012, 5:519-525.
• [10]McDonald SP, Wang Z, Hoy WE: Physical and biochemical predictors of death in an Australian aboriginal cohort. Clin Expl Pharmacol P 1999, 26:618-621.
• [11]Wang Z, Hoy W, Nicol JL, Su Q, Atkins R, Polkinghome KR: Predictive value of nephelometric and high-performance liquid chromatography assays of urine albumin for mortality in a high –risk aboriginal population. Am J Kidney Dis 2008, 52:672-682.
• [12]Warram JH, Gearin G, Laffel L, Krolewski AS: Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996, 7:930-937.
• [13]Rowley KG, Iser DM, Best J, O’Dea K, Leonard D, McDermitt R: Albuminuria in Australian aboriginal people: prevalence and associations with components of the metabolic syndrome. Diabetologia 2000, 43:1397-1403.
• [14]Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA: Microalbuminuria is strongly associated with NIDDM and hypertension, but not with the insulin resistance syndrome: the Hoorn study. Diabetologia 1998, 41:694-700.
• [15]Goetz FC, Jacobs DR, Chavers B, Roel J, Yelle M, Sprafka JM: Risk factors for kidney damage in the adult population of Wadena, Minnesota. Am J Epidemiol 1997, 145:91-102.
• [16]Smulders YM, Rakic M, Stehouwer CDA, Weijers RN, Slaats EH, Silberbusch J: Determinants of progression of microalbuminuria in patients with NIDDM. Diabetes Care 1997, 20:999-1005.
• [17]Koroshi A: Microalbuminuria, is it so important? Hippokratia 2007, 11:105-107.
• [18]Glassock RJ: Prevention of microalbuminuria in type-2 diabetes: millimetres or milligrams. J am Soc Nephrol 2006, 17:3276-3278.
• [19]Hodge AM, Dowse GK, Zimmet PZ: Microalbuminuria, cardiovascular risk factors, and insulin resistance in two populations with a high risk of type 2 diabetes mellitus. Diabet Med 1996, 13:441-449.
• [20]Konen JC, Summerson JH, Bell RA, Curtis LG: Racial differences in symptoms and complications in adults with type-2 diabetes mellitus. Ethn Health 1999, 4:39-49.
• [21]Guo X, Cui J, Wagenknecht LE, Norris JM, Haffner SM, Darwin C, Jinagouda S, Rotter JI, Saad MF: Cosegragation of albuminuria and blood pressure: the InsulinResistance Atherosclerosis (IRAS) family study. Am J Hypertens 2005, 18:823-827.
• [22]Li SH, Szmitko PE, Weisel RD, Wang CH, Fedak PWM, Li RK, Mickle DAG, Verma S: C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation 2004, 109:833-836.
• [23]Albert MA, Glynn RJ, Buring J, Ridker PM: C-reactive protein levels among women of various ethnic groups living in the United Status (from the Women’s Health Study). Am J Cardiol 2004, 93:1238-1242.
• [24]Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, Pepys MB, Campbell LV: Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation 2004, 109:3022-3028.
• [25]Chien KL, Hsu HC, Chen MF, Lee YT: Association of C-reactive protein, smoking and metabolic syndrome among the health check-up population. Acta Cardio Sin 2005, 21:98-104.
• [26]Nakamura M, Onoda T, Itai K, Ohsawa M, Satou K, Sakai T, Segawa T, Sasaki J, Tonari Y, Hiramori K, Okayama A: Association between serum c-reactive protein levels and microalbuminuria: a population-based cross-sectional study in northern Iwate, Japan. Internal Med 2004, 43:919-925.
• [27]Wang Z, Hoy WE: C- reactive protein and the risk of developing type 2 diabetes in aboriginal Australians. Diabetes Res Clin Pr 2007, 76:37-43.
• [28]Festa A, D’agostino R, Howard G, Mykkanen L, Tracy RP, Haffner SM: Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study. Kidney Int 2000, 58:1703-1710.
• [29]Stuveling EM, Bakker SJL, Hillege HL, Burgeruhof JGM, Jone PED, Gans ROB, De ZD: C-reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 2004, 43:791-796.
• [30]Tsioufis C, Dimitriadis K, Chatzis D, Vasiliadou C, Tousoulis D, Papademstriou V, Toutouzas P, Stefanadis C, Kallikazaros I: Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardio 2005, 96:946-951.
• [31]Jousilahti P, Rastenyte D, Tuomilehto J: Serum gamma-glutamyl transferase, self-reported alcohol drinking and the risk of stroke. Stroke 2000, 31:1851-1855.
• [32]Lee DH, Silventoinen K, Hu G, Jacobs DR Jr, Jousilahti P, Sundvall J, Tuomilehto J: Serum gamma-glutamyltransferase predicts non-fatal myocardial infarction and fatal coronary heart disease among 28, 838 middle-aged men and women. Eur Heart J 2006, 27:2170-2176.
• [33]Meisinger C, Lowel H, Heier M, Schneider A, Thorand B: Serum gamma- glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population. J Intern Med 2005, 258:527-535.
• [34]Lee DH, Jacobs DR Jr, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M: Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the coronary artery risk development in young adults (CARDIA) study. Clin Chem 2003, 49:1358-1366.
• [35]Lee DH, Jacobs DR Jr, Gross M, Steffes M: Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the coronary artery risk sevelopment in young adults (CARDIA) study. Clin Chem 2005, 51:1185-1191.
• [36]Hoy WE, Wang Z, VanBuynder P, Backer PRA, McDonald SM, Mathews JD: The natural history of renal disease in Australian aborigines: part 2 albuminuria predicts natural death and renal failure. Kidney Int 2001, 60:249-256.
• [37]Conlgrave KM, Saunders JB, Reznik RB, Whitfield JB: Prediction of alcohol-related ham by laboratory test results. Clin Chem 1993, 39:2266-2270.
• [38]Hoy WE, Mathews JD, McCredie DA, Pugsley DJ, Havhurst BG, Rees M, Kile E, Walker KA, Wang Z: The multidimensional nature of renal disease: rates and associations of albuminuria in an Australian aboriginal community. Kidney Int 1998, 54:1296-1304.
• [39]Conigrave KM, Degenhardt LJ, Whitefield JB, Saunders JB, Helander A, Tabakoff B: CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project. Alcohol Clin Exp Res 2002, 26:332-339.
• [40]Whitfield JB: Serum -glutamyltransferase and risk of disease. Clin Chem 2007, 1:1-2.
• [41]Whitfield JB: Gamma glutamyl transferase. Crit Rev Clin Lab Sci 2001, 38:263-355.
• [42]Lee DH, Blomhoff R, Jacobs DR Jr: Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004, 38:535-539.
• [43]Paolicchi A, Tongiani R, Tonarelli P, Comporti M, Pompella A: Gamma- glutamyl transpeptidase-dependent lipid peroxidation in isolated hepatocytes and HepG2 hepatoma cells. Free Radic Biol Med 1997, 22:853-860.
• [44]Drozdz R, Parmentier C, Hachad H, Leroy P, Siest G, Wellman M: Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med 1998, 25:786-792.
• [45]Bathum L, Petersen HC, Rosholm JU, Hyltoft PP, Vaupel J, Christensen K: Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study. Clin Chem 2001, 47:81-87.
• [46]Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG: Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin Chem 2002, 48:1426-1431.
• [47]Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS: A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011, 305:1553-1559.
• [48]Huo L, Xu M, Li R, Dai M, Wang JG, Ning G, Li XY: Prevalence and prevalence of microalbuminuria in persons with various glucose tolerance levels. ZhongHua YiXue Za Zhi 2007, 87:2537-2540.
• [49]Anvari MS, Boroumand MA, Pourgholi L, Sheikhfathollahi M, Rouhzendeh M, Rabbani S, Goodarzynejad H: Potential link of microalbuminuria with metabolic syndrome in patients undergoing coronary angiography. Arch Med Res 2009, 40:399-405.
• [50]Agrawal V, Vanhecke TE, Rai B, Franklin BA, Sangal RB, McCullough PA: Albuminuria and renal function in obese adults evaluated for obstructive sleep apnea. Nephron Clin Prac 2009, 113:c140-c147.
• [51]Prasad GV, Bandukwala F, Huang M, Zaltman JS: Microalbuminuria post-renal transplantation: relation to cardiovascular risk factors and C-reactive protein. Clin Transplant 2009, 23:313-320.